Skip to main content
. Author manuscript; available in PMC: 2014 Feb 4.
Published in final edited form as: Curr Protein Pept Sci. 2010 Sep;11(6):436–450. doi: 10.2174/138920310791824110

Fig. (4).

Fig. (4)

Schematic representation of different strategies to inhibit EGFR(s). Inhibition of EGFRs can be achieved by targeting extracellular ligand binding domain and/or intracellular tyrosine kinase domain of the receptor. Among the available strategies, mAbs that target the ligand binding domain and TKIs that target intracellular tyrosine kinase activity have been shown to be more successful. mAbs: monoclonal antibodies; siRNA: small interfering ribonucleic acid.